Vera Therapeutics, Inc. (VERA) Ownership
VERA ownership summary
as of October 18, 2026- Institutions
- 118.1% of shares outstanding
- Insiders
- 1.01% of shares outstanding
- Shares outstanding
- 72.1M
- Float
- 52.4M shares available to trade
- Short interest
- 27.23% 17.2M shares short
- Days to cover
- 6.93 short interest up 1.2% vs prior month
- Institutions 118.10%
- Insiders 1.01%
VERA top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 7.98% | 5.7M | $160.2M | +659,658 (+13.0%) | June 30, 2026 |
| 2 | venBio Select Advisor LLC | 7.94% | 5.7M | $159.6M | −165,000 (−2.8%) | June 30, 2026 |
| 3 | State Street Corp | 5.76% | 4.1M | $115.7M | +785,148 (+23.3%) | June 30, 2026 |
| 4 | T. Rowe Price Associates, Inc. | 5.57% | 4.0M | $111.9M | −561,094 (−12.3%) | June 30, 2026 |
| 5 | Deep Track Capital, LP | 5.55% | 4.0M | $111.5M | −106,067 (−2.6%) | June 30, 2026 |
| 6 | Deerfield Management Co | 5.43% | 3.9M | $109.2M | +194,300 (+5.2%) | June 30, 2026 |
| 7 | Kynam Capital Management, LP | 4.01% | 2.9M | $80.6M | −508,165 (−15.0%) | June 30, 2026 |
| 8 | Morgan Stanley - Brokerage Accounts | 3.88% | 2.8M | $78.0M | +2.4M (+659.2%) | June 30, 2026 |
| 9 | Sofinnova Ventures | 3.88% | 2.8M | $77.9M | — | June 30, 2026 |
| 10 | FMR Inc | 3.85% | 2.8M | $77.3M | +97,648 (+3.6%) | June 30, 2026 |
| 11 | Vanguard Capital Management, LLC | 3.82% | 2.8M | $76.8M | +71,806 (+2.7%) | June 30, 2026 |
| 12 | Eversept Partners, LP | 3.07% | 2.2M | $61.7M | +39,484 (+1.8%) | June 30, 2026 |
| 13 | Logos Global Management LP | 3.05% | 2.2M | $61.3M | +2.2M (0.0%) | June 30, 2026 |
| 14 | Integral Health Asset Management, LLC | 2.43% | 1.8M | $48.8M | +150,000 (+9.4%) | June 30, 2026 |
| 15 | Bellevue Group AG | 2.37% | 1.7M | $47.7M | +37 (+0.0%) | June 30, 2026 |
| 16 | Geode Capital Management, LLC | 2.35% | 1.7M | $47.2M | +122,365 (+7.8%) | June 30, 2026 |
| 17 | AllianceBernstein L.P. | 2.21% | 1.6M | $44.4M | +276,801 (+21.1%) | June 30, 2026 |
| 18 | The Goldman Sachs Group Inc | 1.92% | 1.4M | $38.5M | +246,866 (+21.8%) | June 30, 2026 |
| 19 | Frontier Capital Management CO Inc | 1.80% | 1.3M | $36.1M | +743,912 (+134.9%) | June 30, 2026 |
| 20 | Pictet Asset Manangement SA | 1.73% | 1.2M | $34.8M | +197,831 (+18.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 8.2M shares and 4 cut 1.3M.
VERA top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.69% | 1.9M | $54.1M | −3,575 (−0.2%) | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.56% | 1.8M | $51.5M | −35,300 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 2.30% | 1.7M | $46.1M | −19,072 (−1.1%) | September 30, 2026 |
| 4 | T. Rowe Price New Horizons | 1.28% | 924K | $25.8M | −37,752 (−3.9%) | August 31, 2026 |
| 5 | Fidelity Growth Company Fund | 1.21% | 872K | $24.3M | — | August 31, 2026 |
| 6 | International Biotechnology Ord | 1.09% | 788K | $22.0M | — | August 31, 2026 |
| 7 | Fidelity Small Cap Index | 0.97% | 699K | $19.5M | +5,734 (+0.8%) | July 31, 2026 |
| 8 | Pictet-Biotech P USD | 0.94% | 680K | $19.0M | −2,758 (−0.4%) | June 30, 2026 |
| 9 | T. Rowe Price Integrated US Sm Gr Eq | 0.93% | 673K | $18.8M | — | August 31, 2026 |
| 10 | American Century Small Cap Growth Inv | 0.91% | 659K | $18.4M | +105,855 (+19.1%) | June 30, 2026 |
| 11 | iShares Russell 2000 Growth ETF | 0.83% | 598K | $16.7M | −757 (−0.1%) | September 30, 2026 |
| 12 | Candriam Eqs L Biotech C USD Cap | 0.66% | 475K | $13.3M | — | March 31, 2026 |
| 13 | iShares Biotechnology ETF | 0.63% | 456K | $12.7M | −3,456 (−0.8%) | September 30, 2026 |
| 14 | AB Small Cap Growth A | 0.60% | 429K | $12.0M | +29,364 (+7.3%) | August 31, 2026 |
| 15 | AB Discovery Growth A | 0.51% | 368K | $10.3M | +22,406 (+6.5%) | August 31, 2026 |
| 16 | Vanguard Russell 2000 ETF | 0.51% | 367K | $10.2M | +8,540 (+2.4%) | August 31, 2026 |
| 17 | Pictet-Global Megatrend Sel I USD | 0.48% | 346K | $9.6M | +8,576 (+2.5%) | June 30, 2026 |
| 18 | Schwab US Small-Cap ETF™ | 0.45% | 326K | $9.1M | +216 (+0.1%) | September 30, 2026 |
| 19 | Fidelity Extended Market Index | 0.45% | 326K | $9.1M | −2,366 (−0.7%) | August 31, 2026 |
| 20 | Vanguard Explorer Inv | 0.39% | 284K | $7.9M | +236,970 (+502.9%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
VERA insider transactions
latest 12| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-14 | Marshall Fordyce | Sell | $44.05 | 22,951 | $1.0M |
| 2026-02-23 | David Lee Johnson | Sell | $41.98 | 2,579 | $108,266 |
| 2026-02-23 | Joseph R Young | Sell | $41.98 | 3,117 | $130,852 |
| 2026-02-23 | Laurence Matthew Skelton | Sell | $41.98 | 1,582 | $66,412 |
| 2026-02-23 | Marshall Fordyce | Sell | $41.98 | 16,925 | $710,512 |
| 2026-02-23 | Robert Brenner | Sell | $41.98 | 2,151 | $90,299 |
| 2026-02-23 | Sean Grant | Sell | $41.98 | 4,949 | $207,759 |
| 2026-02-23 | William D Turner | Sell | $41.98 | 2,187 | $91,810 |
| 2025-12-11 | Patrick G Enright | Buy | $42.50 | 5,882 | $249,985 |
| 2025-11-11 | Joseph R Young | Sell | $29.06 | 15,000 | $435,900 |
| 2025-06-24 | Patrick G Enright | Buy | $22.35 | 40,607 | $907,566 |
| 2025-06-23 | Patrick G Enright | Buy | $20.87 | 209,393 | $4.4M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
VERA shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns VERA
Institutional investors own 118.1% of Vera Therapeutics's shares and insiders 1.01%. The largest holder is BlackRock Inc with 7.98% of the shares (5.7M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 4 reduced their stake in the latest filings. Short interest is 27.23% of the float, or 6.93 days of average trading volume. The share count rose 213.7% since 2020.
Related: VERA analyst forecast, VERA key metrics. See the VERA stock overview for the latest quote and news.
VERA ownership FAQ
Who owns the most Vera Therapeutics stock?
The largest shareholders of Vera Therapeutics are BlackRock Inc (7.98%), venBio Select Advisor LLC (7.94%), State Street Corp (5.76%), T. Rowe Price Associates, Inc. (5.57%), Deep Track Capital, LP (5.55%).
What percentage of Vera Therapeutics is owned by institutions?
Institutions hold 118.1% of Vera Therapeutics's shares outstanding; insiders hold 1.01%.
Which funds own Vera Therapeutics?
The largest fund holders of Vera Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.69%), State Street® SPDR® S&P® Biotech ETF (2.56%), iShares Russell 2000 ETF (2.30%), T. Rowe Price New Horizons (1.28%), Fidelity Growth Company Fund (1.21%).
What is Vera Therapeutics's short interest?
17.2M shares of Vera Therapeutics were sold short, 27.23% of the float; at the average daily volume it would take 6.93 days to cover.
Are insiders buying or selling Vera Therapeutics?
Of the latest 12 reported insider transactions in Vera Therapeutics (since June 23, 2025), 3 were purchases and 9 were sales.
How many shares of Vera Therapeutics are outstanding?
Vera Therapeutics has 72.1M shares outstanding, of which 52.4M are in the public float.